Literature DB >> 21832236

Type 1 diabetes immunotherapy: is the glass half empty or half full?

Kevan C Herold1, Jeffrey A Bluestone.   

Abstract

Reevaluation of clinical data from the recent failed immunotherapy trials suggests that researchers should continue the quest to cure type 1 diabetes with immune therapies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21832236     DOI： 10.1126/scitranslmed.3002981

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  13 in total

1.  Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets.

Authors:  John F Ryan; Rachel Hovde; Jacob Glanville; Shu-Chen Lyu; Xuhuai Ji; Sheena Gupta; Robert J Tibshirani; David C Jay; Scott D Boyd; R Sharon Chinthrajah; Mark M Davis; Stephen J Galli; Holden T Maecker; Kari C Nadeau
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

Review 2.  Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcome.

Authors:  A M James Shapiro
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 3.  New and future immunomodulatory therapy in type 1 diabetes.

Authors:  James E Tooley; Frank Waldron-Lynch; Kevan C Herold
Journal:  Trends Mol Med       Date:  2012-02-17       Impact factor: 11.951

Review 4.  Prevention of type 1A diabetes mellitus.

Authors:  George S Eisenbarth
Journal:  Endocr Pract       Date:  2012 Sep-Oct       Impact factor: 3.443

Review 5.  Type 1 diabetes.

Authors:  Mark A Atkinson; George S Eisenbarth; Aaron W Michels
Journal:  Lancet       Date:  2013-07-26       Impact factor: 79.321

Review 6.  Extracellular matrix and the maintenance and loss of peripheral immune tolerance in autoimmune insulitis.

Authors:  Carlos O Medina; Nadine Nagy; Paul L Bollyky
Journal:  Curr Opin Immunol       Date:  2018-09-22       Impact factor: 7.486

7.  Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans.

Authors:  David J Klinke
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

8.  IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Yaiza Diaz-de-Durana; Janet Lau; Deborah Knee; Christophe Filippi; Marco Londei; Peter McNamara; Marc Nasoff; Michael DiDonato; Richard Glynne; Ann E Herman
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

9.  Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.

Authors:  Song Xue; Amanda Posgai; Clive Wasserfall; Courtney Myhr; Martha Campbell-Thompson; Clayton E Mathews; Todd Brusko; Alex Rabinovitch; Alexei Savinov; Manuela Battaglia; Desmond Schatz; Michael Haller; Mark A Atkinson
Journal:  Diabetes       Date:  2015-07-16       Impact factor: 9.461

10.  Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.

Authors:  David P Funda; Petra Fundova; Axel Kornerup Hansen; Karsten Buschard
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.